Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Moving Ahead with a New NEJM.org.

Campion EW, Scott LA, Muenning JE, Stern KL, Gartside MA, Frazier KM, Burns NS, Lawlor AJ, Prince JM, Stuart RJ, Morrissey S, Drazen JM.

N Engl J Med. 2018 Feb 8;378(6):574. doi: 10.1056/NEJMe1800731. Epub 2018 Jan 22. No abstract available.

2.

A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF.

Choi J, Xu M, Makowski MM, Zhang T, Law MH, Kovacs MA, Granzhan A, Kim WJ, Parikh H, Gartside M, Trent JM, Teulade-Fichou MP, Iles MM, Newton-Bishop JA, Bishop DT, MacGregor S, Hayward NK, Vermeulen M, Brown KM.

Nat Genet. 2017 Sep;49(9):1326-1335. doi: 10.1038/ng.3927. Epub 2017 Jul 31.

PMID:
28759004
3.

Making An Impact on Clinical Practice and Research in China.

Xiao RP, Wong GW, Prince JM, Gartside M, Zhao J, Wang J, Zhaori G, Drazen JM.

N Engl J Med. 2016 Dec 15;375(24):2391-2392. Epub 2016 Nov 21. No abstract available.

4.

POLE mutations in families predisposed to cutaneous melanoma.

Aoude LG, Heitzer E, Johansson P, Gartside M, Wadt K, Pritchard AL, Palmer JM, Symmons J, Gerdes AM, Montgomery GW, Martin NG, Tomlinson I, Kearsey S, Hayward NK.

Fam Cancer. 2015 Dec;14(4):621-8. doi: 10.1007/s10689-015-9826-8.

PMID:
26251183
5.

Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.

Aoude LG, Gartside M, Johansson P, Palmer JM, Symmons J, Martin NG, Montgomery GW, Hayward NK.

Twin Res Hum Genet. 2015 Apr;18(2):126-33. doi: 10.1017/thg.2015.12. Epub 2015 Mar 19.

PMID:
25787093
6.

Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma.

Aoude LG, Pritchard AL, Robles-Espinoza CD, Wadt K, Harland M, Choi J, Gartside M, Quesada V, Johansson P, Palmer JM, Ramsay AJ, Zhang X, Jones K, Symmons J, Holland EA, Schmid H, Bonazzi V, Woods S, Dutton-Regester K, Stark MS, Snowden H, van Doorn R, Montgomery GW, Martin NG, Keane TM, López-Otín C, Gerdes AM, Olsson H, Ingvar C, Borg A, Gruis NA, Trent JM, Jönsson G, Bishop DT, Mann GJ, Newton-Bishop JA, Brown KM, Adams DJ, Hayward NK.

J Natl Cancer Inst. 2014 Dec 13;107(2). pii: dju408. doi: 10.1093/jnci/dju408. Print 2015 Feb.

7.

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors.

Marusiak AA, Edwards ZC, Hugo W, Trotter EW, Girotti MR, Stephenson NL, Kong X, Gartside MG, Fawdar S, Hudson A, Breitwieser W, Hayward NK, Marais R, Lo RS, Brognard J.

Nat Commun. 2014 May 22;5:3901. doi: 10.1038/ncomms4901.

8.

POT1 loss-of-function variants predispose to familial melanoma.

Robles-Espinoza CD, Harland M, Ramsay AJ, Aoude LG, Quesada V, Ding Z, Pooley KA, Pritchard AL, Tiffen JC, Petljak M, Palmer JM, Symmons J, Johansson P, Stark MS, Gartside MG, Snowden H, Montgomery GW, Martin NG, Liu JZ, Choi J, Makowski M, Brown KM, Dunning AM, Keane TM, López-Otín C, Gruis NA, Hayward NK, Bishop DT, Newton-Bishop JA, Adams DJ.

Nat Genet. 2014 May;46(5):478-481. doi: 10.1038/ng.2947. Epub 2014 Mar 30.

9.

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.

Byron SA, Chen H, Wortmann A, Loch D, Gartside MG, Dehkhoda F, Blais SP, Neubert TA, Mohammadi M, Pollock PM.

Neoplasia. 2013 Aug;15(8):975-88.

10.

Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma.

Dutton-Regester K, Kakavand H, Aoude LG, Stark MS, Gartside MG, Johansson P, O'Connor L, Lanagan C, Tembe V, Pupo GM, Haydu LE, Schmidt CW, Mann GJ, Thompson JF, Scolyer RA, Hayward NK.

Pigment Cell Melanoma Res. 2013 Nov;26(6):852-60. doi: 10.1111/pcmr.12153. Epub 2013 Aug 23.

PMID:
23890154
11.

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.

Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, Goodfellow PJ, Pollock PM.

PLoS One. 2012;7(2):e30801. doi: 10.1371/journal.pone.0030801. Epub 2012 Feb 23. Erratum in: PLoS One. 2012;7(2):doi/10.1371/annotation/0bfaecca-0f87-43fe-97cc-f2ae3ddeb6d5.

12.

Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.

Stark MS, Woods SL, Gartside MG, Bonazzi VF, Dutton-Regester K, Aoude LG, Chow D, Sereduk C, Niemi NM, Tang N, Ellis JJ, Reid J, Zismann V, Tyagi S, Muzny D, Newsham I, Wu Y, Palmer JM, Pollak T, Youngkin D, Brooks BR, Lanagan C, Schmidt CW, Kobe B, MacKeigan JP, Yin H, Brown KM, Gibbs R, Trent J, Hayward NK.

Nat Genet. 2011 Dec 25;44(2):165-9. doi: 10.1038/ng.1041.

13.

A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma.

Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, Gartside M, Cust AE, Haq R, Harland M, Taylor JC, Duffy DL, Holohan K, Dutton-Regester K, Palmer JM, Bonazzi V, Stark MS, Symmons J, Law MH, Schmidt C, Lanagan C, O'Connor L, Holland EA, Schmid H, Maskiell JA, Jetann J, Ferguson M, Jenkins MA, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper JL, Whiteman DC, Pharoah PD, Easton DF, Dunning AM, Newton-Bishop JA, Montgomery GW, Martin NG, Mann GJ, Bishop DT, Tsao H, Trent JM, Fisher DE, Hayward NK, Brown KM.

Nature. 2011 Nov 13;480(7375):99-103. doi: 10.1038/nature10630.

14.

FGFR2 mutations are rare across histologic subtypes of ovarian cancer.

Byron SA, Gartside MG, Wellens CL, Goodfellow PJ, Birrer MJ, Campbell IG, Pollock PM.

Gynecol Oncol. 2010 Apr;117(1):125-9. doi: 10.1016/j.ygyno.2009.12.002. Epub 2010 Jan 27.

PMID:
20106510
15.

Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.

Gartside MG, Chen H, Ibrahimi OA, Byron SA, Curtis AV, Wellens CL, Bengston A, Yudt LM, Eliseenkova AV, Ma J, Curtin JA, Hyder P, Harper UL, Riedesel E, Mann GJ, Trent JM, Bastian BC, Meltzer PS, Mohammadi M, Pollock PM.

Mol Cancer Res. 2009 Jan;7(1):41-54. doi: 10.1158/1541-7786.MCR-08-0021.

16.

Global expression profiling of sex cord stromal tumors from Men1 heterozygous mice identifies altered TGF-beta signaling, decreased Gata6 and increased Csf1r expression.

Mould AW, Duncan R, Serewko-Auret M, Loffler KA, Biondi C, Gartside M, Kay GF, Hayward NK.

Int J Cancer. 2009 Mar 1;124(5):1122-32. doi: 10.1002/ijc.24057.

17.

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.

Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB, Powell MA, Goodfellow PJ, Pollock PM.

Cancer Res. 2008 Sep 1;68(17):6902-7. doi: 10.1158/0008-5472.CAN-08-0770. Erratum in: Cancer Res. 2008 Dec 1;68(23):10005.

18.

Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.

Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, Mohammadi M, Futreal PA, Stratton MR, Trent JM, Goodfellow PJ.

Oncogene. 2007 Nov 1;26(50):7158-62. Epub 2007 May 21.

19.

Global expression profiling of murine MEN1-associated tumors reveals a regulatory role for menin in transcription, cell cycle and chromatin remodelling.

Mould AW, Duncan R, Serewko-Auret M, Loffler KA, Biondi C, Gartside M, Kay GF, Hayward NK.

Int J Cancer. 2007 Aug 15;121(4):776-83.

20.

Lack of augmentation of tumor spectrum or severity in dual heterozygous Men1 and Rb1 knockout mice.

Loffler KA, Biondi CA, Gartside MG, Serewko-Auret MM, Duncan R, Tonks ID, Mould AW, Waring P, Muller HK, Kay GF, Hayward NK.

Oncogene. 2007 Jun 7;26(27):4009-17. Epub 2006 Dec 18.

PMID:
17173065
21.

Broad tumor spectrum in a mouse model of multiple endocrine neoplasia type 1.

Loffler KA, Biondi CA, Gartside M, Waring P, Stark M, Serewko-Auret MM, Muller HK, Hayward NK, Kay GF.

Int J Cancer. 2007 Jan 15;120(2):259-67.

22.

Association between chronic fatigue syndrome and the corticosteroid-binding globulin gene ALA SER224 polymorphism.

Torpy DJ, Bachmann AW, Gartside M, Grice JE, Harris JM, Clifton P, Easteal S, Jackson RV, Whitworth JA.

Endocr Res. 2004 Aug;30(3):417-29.

PMID:
15554358
23.

Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues.

Biondi CA, Gartside MG, Waring P, Loffler KA, Stark MS, Magnuson MA, Kay GF, Hayward NK.

Mol Cell Biol. 2004 Apr;24(8):3125-31.

24.

Targeting and conditional inactivation of the murine Men1 locus using the Cre recombinase: loxP system.

Biondi C, Gartside M, Tonks I, Paterson C, Hayward NK, Kay GF.

Genesis. 2002 Feb;32(2):150-1. No abstract available.

PMID:
11857805
25.

Characterization of RasGRP2, a plasma membrane-targeted, dual specificity Ras/Rap exchange factor.

Clyde-Smith J, Silins G, Gartside M, Grimmond S, Etheridge M, Apolloni A, Hayward N, Hancock JF.

J Biol Chem. 2000 Oct 13;275(41):32260-7.

26.

Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia.

Bellomo D, Headrick JP, Silins GU, Paterson CA, Thomas PS, Gartside M, Mould A, Cahill MM, Tonks ID, Grimmond SM, Townson S, Wells C, Little M, Cummings MC, Hayward NK, Kay GF.

Circ Res. 2000 Feb 4;86(2):E29-35.

27.

Evidence for persistent dysfunction of wild-type aldosterone synthase gene in glucocorticoid-treated familial hyperaldosteronism type I.

Stowasser M, Taylor WL, Gartside MG, Tunny TJ, Gordon RD.

J Hypertens. 1997 Dec;15(12 Pt 2):1729-33.

PMID:
9488230
28.
29.

In familial hyperaldosteronism type I, hybrid gene-induced aldosterone production dominates that induced by wild-type genes.

Stowasser M, Gartside MG, Taylor WL, Tunny TJ, Gordon RD.

J Clin Endocrinol Metab. 1997 Nov;82(11):3670-6.

PMID:
9360524
30.

Increased resistance to Anaplasma marginale infection in cattle chronically infected with Theileria buffeli (syn. T. orientalis).

Gale KR, Leatch G, Dimmock CM, Gartside MG.

Vet Parasitol. 1997 May;69(3-4):187-96.

PMID:
9195728
31.

Insertion/deletion polymorphism of the angiotensin-converting enzyme gene and loss of the insertion allele in aldosterone-producing adenoma.

Tunny TJ, Xu L, Richardson KA, Stowasser M, Gartside M, Gordon RD.

J Hum Hypertens. 1996 Dec;10(12):827-30.

PMID:
9140790
32.

Anaplasma marginale: detection of carrier cattle by PCR-ELISA.

Gale KR, Dimmock CM, Gartside M, Leatch G.

Int J Parasitol. 1996 Oct;26(10):1103-9.

PMID:
8982791
33.

Different allelic patterns at chromosome 11q13 in paired aldosterone-producing tumours and blood DNA.

Gordon R, Gartside M, Tunny T, Stowasser M.

Clin Exp Pharmacol Physiol. 1996 Jun-Jul;23(6-7):594-6.

PMID:
8800595
34.

Peripheral blood lymphocyte proliferative responses in cattle infected with or vaccinated against Anaplasma marginale.

Gale KR, Gartside MG, Dimmock CM, Zakrzewski H, Leatch G.

Parasitol Res. 1996;82(6):551-62.

PMID:
8832738
35.

Anaplasma marginale: failure of sera from immune cattle to confer protection in passive-transfer experiments.

Gale KR, Leatch G, Gartside M, Dimmock CM.

Parasitol Res. 1992;78(5):410-5.

PMID:
1495919
36.

Early pregnancy termination: a comparison between vacuum aspiration and medical abortion using prostaglandin (16,16 dimethyl-trans-delta 2-PGE1 methyl ester) or the antiprogestogen RU 486.

Iqbal PK, Hopkins RE, Stevenson TC, Mayers FN, Gartside MW.

Br J Obstet Gynaecol. 1988 Aug;95(8):827-8. No abstract available.

PMID:
3166959
37.

The prognostic value of human placental lactogen (HPL) levels in threatened abortion.

Gartside MW, Tindall VR.

Br J Obstet Gynaecol. 1975 Apr;82(4):303-9.

PMID:
1125152

Supplemental Content

Loading ...
Support Center